Brokerages Set Syneos Health Inc (NASDAQ:SYNH) Target Price at $59.50
Syneos Health Inc (NASDAQ:SYNH) has received an average rating of “Buy” from the eleven brokerages that are currently covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $59.50.
SYNH has been the topic of several research reports. ValuEngine upgraded shares of Syneos Health from a “sell” rating to a “hold” rating in a research note on Wednesday. Jefferies Financial Group upped their price target on shares of Syneos Health from $62.00 to $65.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. KeyCorp upped their price target on shares of Syneos Health from $63.00 to $65.00 and gave the company an “overweight” rating in a research note on Tuesday, September 3rd. Credit Suisse Group upped their price target on shares of Syneos Health from $56.00 to $58.00 and gave the company an “outperform” rating in a research note on Friday, August 23rd. Finally, SunTrust Banks upped their price target on shares of Syneos Health to $68.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th.
A number of institutional investors have recently made changes to their positions in SYNH. Financial Gravity Wealth Inc. bought a new position in Syneos Health in the 2nd quarter valued at approximately $29,000. Quest Capital Management Inc. ADV purchased a new position in shares of Syneos Health during the 3rd quarter worth about $99,000. CSat Investment Advisory L.P. purchased a new position in shares of Syneos Health during the 2nd quarter worth about $136,000. Convergence Investment Partners LLC purchased a new position in shares of Syneos Health during the 3rd quarter worth about $147,000. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Syneos Health by 48.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,272 shares of the company’s stock worth $167,000 after purchasing an additional 1,073 shares during the period.
Syneos Health (NASDAQ:SYNH) last announced its earnings results on Thursday, October 31st. The company reported $0.87 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.82 by $0.05. Syneos Health had a net margin of 1.86% and a return on equity of 10.13%. The company had revenue of $1.18 billion during the quarter, compared to the consensus estimate of $1.18 billion. During the same period in the previous year, the firm posted $0.75 earnings per share. The company’s revenue was up 5.6% on a year-over-year basis. On average, sell-side analysts anticipate that Syneos Health will post 2.79 earnings per share for the current year.
About Syneos Health
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Featured Article: How to Trade Using Analysts Ratings
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.